title: Cutaneous pseudolymphoma following administration of lornoxicam.
authors.forename: Nikolaos G
authors.initials: NG
authors.lastname: Stavrianeas
authors.forename: Alexander C
authors.initials: AC
authors.lastname: Katoulis
authors.forename: Evangelia
authors.initials: E
authors.lastname: Bozi
authors.forename: Eugenia
authors.initials: E
authors.lastname: Toumbis-Ioannou
authors.forename: Antonios I
authors.initials: AI
authors.lastname: Kanelleas
authors.forename: Michael
authors.initials: M
authors.lastname: Makris
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Kalogeromitros
authors.forename: Ioannis
authors.initials: I
authors.lastname: Panayiotides
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects*; D001416:Back Pain / Q000188:drug therapy; D006801:Humans; D008297:Male; D010894:Piroxicam / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D019310:Pseudolymphoma / Q000139:chemically induced*; D012871:Skin Diseases / Q000139:chemically induced*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam; C059451:lornoxicam